应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
AZN 阿斯利康
盘后交易 03-02 16:28:03 EST
203.73
-4.72
-2.26%
盘后
203.73
+0.00
0.00%
16:15 EST
最高
206.30
最低
203.34
成交量
171.53万
今开
205.64
昨收
208.45
日振幅
1.42%
总市值
3,160亿
流通市值
3,146亿
总股本
15.51亿
成交额
3.51亿
换手率
0.11%
流通股本
15.44亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
传AI芯片制造商Cerebras已秘密提交IPO申请 估值或达220亿美元
智通财经 · 02-25
传AI芯片制造商Cerebras已秘密提交IPO申请 估值或达220亿美元
超级大洗牌！跨国药企中国市场最新排名
健识局 · 02-16
超级大洗牌！跨国药企中国市场最新排名
倍择瑞®治疗未控制哮喘的KALOS与LOGOS III期试验取得具有临床意义的阳性结果 相关成果发表于《柳叶刀-呼吸病学杂志》
美通社 · 02-13
倍择瑞®治疗未控制哮喘的KALOS与LOGOS III期试验取得具有临床意义的阳性结果 相关成果发表于《柳叶刀-呼吸病学杂志》
异动解读 | 业绩强劲叠加口服减肥药进展，阿斯利康盘中大涨5.02%
异动解读 · 02-12
异动解读 | 业绩强劲叠加口服减肥药进展，阿斯利康盘中大涨5.02%
1至8批国家集采药品接续采购开标；阿斯利康去年全球总营收达587.39亿美元丨医药早参
每日经济新闻 · 02-11
1至8批国家集采药品接续采购开标；阿斯利康去年全球总营收达587.39亿美元丨医药早参
阿斯利康(AZN.US)拟走“低价高量”路线 进军全球减肥药市场
智通财经 · 02-10
阿斯利康(AZN.US)拟走“低价高量”路线 进军全球减肥药市场
美股前瞻 | 三大股指期货齐涨 零售销售数据公布前美债抢跑“降息行情”
智通财经 · 02-10
美股前瞻 | 三大股指期货齐涨 零售销售数据公布前美债抢跑“降息行情”
阿斯利康(AZN.US)CFO：美国定价影响已纳入2026年业绩指引，该影响在一定程度上存在。
格隆汇 · 02-10
阿斯利康(AZN.US)CFO：美国定价影响已纳入2026年业绩指引，该影响在一定程度上存在。
阿斯利康2025年营收587.39亿美元
南方财经网 · 02-10
阿斯利康2025年营收587.39亿美元
阿斯利康2025年产品销售额同比增长9%，核心每股收益同比增长11%
老虎资讯综合 · 02-10
阿斯利康2025年产品销售额同比增长9%，核心每股收益同比增长11%
康泰生物与阿斯利康4亿美元合作告吹，涉疫苗研发生产
新京报 · 02-09
康泰生物与阿斯利康4亿美元合作告吹，涉疫苗研发生产
28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业
第一财经 · 02-08
28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业
阿斯利康(AZN.US)双抗1类新药在中国获批临床
智通财经网 · 02-06
阿斯利康(AZN.US)双抗1类新药在中国获批临床
Saphnelo皮下剂型申请遭FDA驳回，阿斯利康：承诺与FDA密切合作以尽快推进申请
格隆汇 · 02-03
Saphnelo皮下剂型申请遭FDA驳回，阿斯利康：承诺与FDA密切合作以尽快推进申请
阿斯利康狼疮药自行注射剂型申请遭FDA驳回
格隆汇 · 02-03
阿斯利康狼疮药自行注射剂型申请遭FDA驳回
股价一度跌近2%！阿斯利康(AZN.US)狼疮药自行注射剂型申请遭FDA驳回
智通财经 · 02-03
股价一度跌近2%！阿斯利康(AZN.US)狼疮药自行注射剂型申请遭FDA驳回
财报前瞻｜阿斯利康本季度营收预计增8.99%，机构观点偏乐观
财报Agent · 02-03
财报前瞻｜阿斯利康本季度营收预计增8.99%，机构观点偏乐观
加码美国市场：阿斯利康登陆纽交所，伦敦地位或被削弱
智通财经 · 02-02
加码美国市场：阿斯利康登陆纽交所，伦敦地位或被削弱
中金：石药集团(01093)与阿斯利康达成重磅合作 维持“跑赢行业”评级
智通财经 · 02-02
中金：石药集团(01093)与阿斯利康达成重磅合作 维持“跑赢行业”评级
阿斯利康全球CEO：中国在全球医药创新生态中不可或缺
中国新闻网 · 01-30
阿斯利康全球CEO：中国在全球医药创新生态中不可或缺
公司概况
公司名称：
阿斯利康
所属市场：
NYSE
上市日期：
--
主营业务：
阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。
发行价格：
--
{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":203.73,"timestamp":1772485200000,"preClose":208.45,"halted":0,"volume":1715299,"hourTrading":{"tag":"盘后","latestPrice":203.73,"preClose":203.73,"latestTime":"16:15 EST","volume":75987,"amount":15480831.51,"timestamp":1772486114785,"change":0,"changeRate":0,"amplitude":0.000822},"delay":0,"changeRate":-0.022643319740945068,"floatShares":1544000000,"shares":1551000000,"eps":6.54,"marketStatus":"盘后交易","change":-4.72,"latestTime":"03-02 16:28:03 EST","open":205.64,"high":206.3,"low":203.34,"amount":350941547.44603,"amplitude":0.0142,"askPrice":206,"askSize":5,"bidPrice":203.3,"bidSize":1,"shortable":3,"etf":0,"ttmEps":6.54,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772499600000},"marketStatusCode":4,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":208.45,"dividendRate":0.015347,"preHourTrading":{"tag":"盘前","latestPrice":205.5,"preClose":208.45,"latestTime":"09:29 EST","volume":11879,"amount":2446899.14112,"timestamp":1772461799749,"change":-2.95,"changeRate":-0.014152,"amplitude":0.011609},"postHourTrading":{"tag":"盘后","latestPrice":203.73,"preClose":203.73,"latestTime":"16:15 EST","volume":75987,"amount":15480831.51,"timestamp":1772486114785,"change":0,"changeRate":0,"amplitude":0.000822},"volumeRatio":0.931288,"impliedVol":0.2825,"impliedVolPercentile":0.5976},"requestUrl":"/m/hq/s/AZN/wiki","defaultTab":"wiki","newsList":[{"id":"2614737497","title":"传AI芯片制造商Cerebras已秘密提交IPO申请 估值或达220亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614737497","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614737497?lang=zh_cn&edition=full","pubTime":"2026-02-25 10:34","pubTimestamp":1771986843,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据报道，与英伟达 和AMD竞争的人工智能芯片制造商Cerebras已秘密提交首次公开募股申请。此前的报道显示，Cerebras目标是在2026年第二季度进行首次公开募股。上月，Cerebras与OpenAI签署了一项价值数十亿美元的多年协议，为其提供750兆瓦的计算能力。据报道，Cerebras还在洽谈筹集10亿美元资金，这将使公司估值达到220亿美元。Cerebras最初于2024年9月申请公开上市，但因联邦政府对其与阿布扎比AI公司G42关系的审查而陷入停滞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1084165304.USD","IE00BZ199S13.USD","LU2471134952.CNY","LU2271345857.HKD","BK4573","LU1974910355.USD","LU2471134523.USD","IE00B3S45H60.SGD","LU1303367103.USD","LU1316542783.SGD","LU0256863811.USD","LU0444971666.USD","LU1366192091.USD","NVD3.UK","SG9999015945.SGD","SGXZ99366536.SGD","LU0642271901.SGD","LU0211327993.USD","LU2430703095.HKD","LU0310800379.SGD","IE0009G5SDU7.USD","LU0788109477.HKD","LU2433249047.HKD","LU2756315664.SGD","LU0345770993.USD","LU0347712357.USD","LU0354030511.USD","LU1951198990.SGD","IE00B4JS1V06.HKD","NVDS.UK","AMDU","IE00B7KXQ091.USD","IE00B1XK9C88.USD","LU0823421333.USD","IE000YTNTUN2.SGD","LU2592432038.USD","IE0009356076.USD","LU0061474960.USD","LU1548497426.USD","NVDB","LU0308772762.SGD","LU1989764664.SGD","LU2452424414.USD","LU2087625088.SGD","LU1861558580.USD","NVD","LU1868837136.USD","LU2357305700.SGD","LU1366333091.USD","NVDY","AMYY","IE0004445015.USD","LU0061475181.USD","LU2089284900.SGD","LU0316494557.USD","LU0154236417.USD","LU0210533765.USD","LU2098885051.SGD","IE0001KFT4U8.USD","IE00BKDWB100.SGD","AMDG","LU2505996681.GBP","LU0965509101.SGD","LU2286300806.USD","LU0267386448.USD","LU2491050071.SGD","LU2355687059.USD","LU0786609619.USD","LU1934455277.USD","IE00BDCRKT87.USD","SGXZ31699556.SGD","NVDD","LU2461242641.AUD","IE00BZ1G4Q59.USD","LU2097344357.USD","LU2054465674.USD","IE00B5949003.HKD","LU2543165471.USD","IE000KEQY171.SGD","LU1935042991.SGD","LU0096362180.USD","LU1720051108.HKD","SG9999015341.SGD","LU0265550946.USD","LU2552382215.SGD","LU0708994859.HKD","LU2065170008.USD","HK0000306701.USD","LU2247934214.USD","LU0203202063.USD","LU2456880835.USD","NVDS","LU0683600562.USD","SG9999014880.SGD","LU2462157665.USD","LU1718418525.SGD","LU0276348264.USD","LU2487616109.SGD","LU2361044865.SGD","IE0004086264.USD","IE00BN29S564.USD","LU2552382132.HKD","LU0882574139.USD","LU1861215975.USD","LU1069344957.HKD","IE00BK4W5L77.USD","LU0056508442.USD","LU1153585028.USD","LU2458330243.SGD","LU0289961442.SGD","LU1989772923.USD","LU2242650005.HKD","LU1804176565.USD","LU1435385759.SGD","IE00BQXX3C00.GBP","NVDU","HK0000320264.USD","LU0511384066.AUD","LU1674673428.USD","LU2242649171.HKD","LU1880398554.USD","LU2290526834.HKD","LU0957808578.USD","LU0128525929.USD","LU0323591593.USD","LU1691799644.USD","LU0225283273.USD","LU0689472784.USD","IE00B775SV38.USD","IE00BJJMRY28.SGD","LU1267930730.SGD","LU2125909916.SGD","IE00BMPRXQ63.HKD","LU1674673691.USD","LU0472753341.HKD","LU0061474705.USD","LU2322448957.HKD","LU1261432733.SGD","IE0034235303.USD","LU1267930573.SGD","LU0158827781.USD","LU2360106780.USD","IE0004091025.USD","BK4550","LU0029864427.USD","LU2023250504.SGD","LU0077335932.USD","LU1633808545.USD","LU1066051225.USD","IE00BFSS7M15.SGD","IE00B1BXHZ80.USD","SG9999004303.SGD","LU2756315318.SGD","HK0000914686.HKD","LU1116320901.HKD","LU2403377893.USD","IE00BJJMRX11.SGD","LU1267930490.SGD","LU2491049909.HKD","LU1429558221.USD","LU0081259029.USD","LU0170899867.USD","LU2125909593.SGD","BK4598","LU2746668974.SGD","LU2125909247.SGD","BK4614","LU0964807845.USD","BK4527","LU0053666078.USD","BK4534","SG9999015358.SGD","LU1066053197.SGD","2NVD.UK","LU2023250330.USD","LU0274383776.USD","LU2087621335.USD","LU2089985449.USD","LU1923622614.USD","LU2092937148.SGD","BK4566","IE00BKPKM429.USD","LU0175139822.USD","LU1623119135.USD","LU1935042488.USD","LU1712237335.SGD","LU2471134879.HKD","LU0861579265.USD","LU0096364046.USD","SG9999014906.USD","SGXZ51526630.SGD","BK4587","LU1917777945.USD","BK4512","LU0215105999.USD","LU2236285917.USD","LU1868836591.USD","LU1914381329.SGD","LU0127658192.USD","LU0823414478.USD","HK0000914660.USD","LU0957791311.USD","LU0348723411.USD","BK4581","LU0889565833.HKD","LU0097036916.USD","LU2272731865.HKD","LU2322448791.USD","LU2111349929.HKD","LU2463028550.USD","LU1988902786.USD","LU0672654240.SGD","NVIW.SI","ANV","LU0109391861.USD","LU2125154935.USD","LU2471134796.USD","SNVD.UK","LU2381873111.SGD","LU0823414551.USD","LU0187121727.USD","BK4605","LU2860962120.EUR","BK4529","SG9999015952.SGD","LU0345769631.USD","NVDX","SG9999014567.USD","IE0034235295.USD","IE00BMPRXN33.USD","LU2602419157.SGD","LU0787776722.HKD","AMUU","LU0080751232.USD","AMDD","LU2272731600.USD","LU1496350171.SGD","IE00BKVL7J92.USD","LU0965509010.AUD","LU1992135399.USD","NVDG","GB00BDT5M118.USD","IE0005OL40V9.USD","LU1323610961.USD","IE00BD6J9T35.USD","LU1066051811.HKD","LU2237438978.USD","LU1934455194.USD","LU1037948897.HKD","LU1923623000.USD","LU2028103732.USD","BK4612","LU0234572021.USD","LU1951200564.SGD","LU0345768740.USD","LU2294711713.HKD","LU1035775433.USD","LU2125909759.SGD","IE00B3M56506.USD","IE0034235188.USD","IE00B3SWFQ91.USD","LU2430703251.USD","LU1803068979.SGD","LU1232071149.USD","LU0708995401.HKD","LU2211815571.USD","LU0107464264.USD","LU0210528500.USD","LU0868494708.USD","BK4532","LU0079474960.USD","LU0494093205.USD","LU1280957306.USD","LU2491050154.USD","LU0528227936.USD","IE00BQXX3D17.EUR","LU0069063385.USD","LU1791710582.SGD","LU1145028129.USD","LU0198837287.USD","LU1815333072.USD","LU1064131342.USD","SG9999014898.SGD","SG9999014542.SGD","LU0345769128.USD","IE00BYXW3230.USD","LU0353189680.USD","NVDW","LU1551013342.USD","LU2430703178.SGD","LU1989764748.USD","BK4579","SG9999018865.SGD","LU0072462426.USD","LU1868836757.USD","LU2750360641.GBP","LU0048584097.USD","LU1852331112.SGD","LU0210536198.USD","LU2413666426.HKD","LU1720051017.SGD","LU0354030438.USD","LU2750360997.AUD","SG9999014575.USD","LU1989772840.SGD","NVDQ","LU1821325948.USD","LU2249611893.SGD","LU1127390331.HKD","LU2106854487.HKD","LU0640476718.USD","LU0943347566.SGD","LU0256863902.USD","BK4533","LU1861559042.SGD","LU1791710400.SGD","LU2213496289.HKD","LU1815336760.USD","LU0390134368.USD","IE00BJTD4V19.USD","LU0985320562.USD","SG9999002232.USD","IE00BJTD4N35.SGD","LU1935043536.SGD","LU0417517546.SGD","LU2896262040.SGD","LU0820562030.AUD","LU1868837300.USD","AMDY","SG9999000418.SGD","LU1861220033.SGD","LU2063271972.USD","LU1935043023.USD","LU1923622291.USD","LU2746668461.USD","LU2552382058.USD","DAMD","BK4549","LU0823434740.USD","HK0000320223.HKD","LU0006306889.USD","HK0000306685.HKD","LU1571399168.USD","LU2089283258.USD","BK4575","LU2237957811.SGD","LU2361045086.USD","LU0689626769.HKD","LU2244417387.USD","LU2237957902.USD","LU0320765059.SGD","LU2505996509.AUD","LU2108987350.USD","LU2168564495.EUR","LU0157215616.USD","LU1642822529.SGD","AMDW","NVD2.UK","BK4554","BK4592","LU2168564065.EUR","LU0289960550.SGD","SG9999014914.USD","LU1868836914.USD","SG9999017495.SGD","LU2473716301.USD","LU2506951792.HKD","LU0724617625.USD","LU0965509283.SGD","LU0011850046.USD","LU1935042215.USD","SG9999014559.SGD","IE00BWXC8680.SGD","LU0476273544.USD","LU1983260115.SGD","LU0353189763.USD","LU0719512351.SGD","IE00B19Z8X17.USD","BK4551","IE00BHPRN162.USD","LU2413666699.HKD","SG9999015986.USD","LU0082616367.USD","IE00BJLML261.HKD","BK4543","LU2250418816.HKD","LU0345770308.USD","LU0444973449.USD","LU1992135472.HKD","LU1699723380.USD","LU0823421416.USD","LU0265550359.USD","LU2264538146.SGD","LU2265009873.SGD","LU0124676726.USD","LU1839511570.USD","LU2361044949.HKD","LU0868494617.USD","LU1116320737.USD","LU0345768153.USD","LU2168564222.USD","LU1119994496.HKD","SG9999001424.SGD","LU1778281490.HKD","LU0238689110.USD","IE0004445239.USD","LU0234570918.USD","LU2125154778.USD","BK4503","LU2417539215.USD","LU2420271590.USD","IE000W1ABFV2.USD","LU2065171311.SGD","LU0820561909.HKD","LU0965508806.USD","BK4141","LU0106261372.USD","LU0289739343.SGD","3NVD.UK","IE00BMPRXR70.SGD","LU2360107168.USD","DIPS","LU0557290698.USD","SG9999002224.SGD","LU1242518931.SGD","SGXZ81514606.USD","BK4608","LU0820561818.USD","LU0342679015.USD","LU1496350502.SGD","AZN","IE0003U64NQ7.SGD","LU2065171402.SGD","LU2077746001.SGD","LU0251132253.USD","LU1244550577.SGD","LU0310799852.SGD","LU1629891620.HKD","IE00BK4W5M84.HKD","LU1934455863.HKD","LU1721428933.USD","LU0266013472.USD","LU2092627202.USD","LU1244550221.USD","LU0823434583.USD","LU2097344431.USD","SG9999018857.SGD","BK4548","LU0057025933.USD","LU2931357623.SGD","IE00B19Z9505.USD","LU1861127337.USD","IE000ITXATA3.USD","LU2357125470.USD","LU1880398471.USD","LU2065169927.USD","SG9999015978.USD","IE00BQXX3F31.USD","IE00B4YYXB79.USD","LU2458330169.SGD","LU1066051498.USD","LU2326559502.SGD","LU2083900584.USD","IE00B775H168.HKD","LU1037948541.HKD","BK4588","LU1814569148.SGD","IE00B19Z8W00.USD","NVII","LU0942090050.USD","IE00BFSS8Q28.SGD","LU0158827948.USD","LU0203201768.USD","LU1242518857.USD","LU0979878070.USD","LU1244550494.USD","LU2272731782.SGD","LU2360032135.SGD","LU2168563687.JPY","LU0109392836.USD","LU0094547139.USD","LU2191332357.HKD","LU2023251221.USD","IE00BDRTCR15.USD","LU0211328371.USD","LU2168564149.EUR","BK4567","LU0466842654.USD","BK4585","LU1551013425.SGD","LU0070217475.USD","SGXZ23171101.USD"],"gpt_icon":1},{"id":"2611486068","title":"超级大洗牌！跨国药企中国市场最新排名","url":"https://stock-news.laohu8.com/highlight/detail?id=2611486068","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611486068?lang=zh_cn&edition=full","pubTime":"2026-02-16 23:02","pubTimestamp":1771254130,"startTime":"0","endTime":"0","summary":"1月份，跨国药企基本都披露了2025年业绩。礼来则以45%的增幅，营收达651.79亿美元成功反超默沙东，排名第三。而在中国市场，2025年1月，替尔泊肽降糖和减重两项适应症相继上市。2022年至2024年，阿斯利康与默沙东争夺跨国药企中国区营收的“NO.1”，“销售一哥”的宝座每年轮流坐庄。此外，诺华已宣布在中国建立核药生产基地，以支持“派威妥”等放射性药物在中国市场的长期供应。跨国药企把全球创新好药带到中国，才是最好的市场策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MCHI","RHHBY","CWEB","BK4599","LLY","NVS","BK4007","BK4532","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","MRK","BK4614","DRAG","LU1093756168.USD","ASHS","KWEB","AZN","LU1093756325.SGD","BK4585","NVOH","NVO","CQQQ","ASHR","LU0963586101.USD","LU0154236417.USD","BK4504","BK4588","NVOX"],"gpt_icon":1},{"id":"2611713190","title":"倍择瑞®治疗未控制哮喘的KALOS与LOGOS III期试验取得具有临床意义的阳性结果 相关成果发表于《柳叶刀-呼吸病学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=2611713190","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611713190?lang=zh_cn&edition=full","pubTime":"2026-02-13 15:43","pubTimestamp":1770968580,"startTime":"0","endTime":"0","summary":"完整结果可查阅《柳叶刀-呼吸病学杂志》。KALOS与LOGOS试验表明，布地格福固定三联吸入疗法能够同时发挥ICS、LAMA和LABA的疗效，改善肺功能。KALOS与LOGOS研究结果有力地证实，布地格福固定三联吸入疗法有望为该类型哮喘患者带来健康获益。\" 在KALOS与LOGOS试验中，布地格福吸入气雾剂未出现新的安全性或耐受性问题。KALOS与LOGOS研究共纳入约4300名随机分组患者。KALOS和LOGOS试验的主要终点和治疗比较方案因监管申报途径的不同而有所差异。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4887756_ZH87756_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0058720904.USD","BK4568","AZN","LU0289739699.SGD","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","LU2236285917.USD","BK4007","LU2417539215.USD","LU1829250122.USD","BK4585","LU2456880835.USD","LU2462157665.USD","BK4134","BK4588","III"],"gpt_icon":0},{"id":"1196396752","title":"异动解读 | 业绩强劲叠加口服减肥药进展，阿斯利康盘中大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196396752","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196396752?lang=zh_cn&edition=full","pubTime":"2026-02-12 01:21","pubTimestamp":1770830507,"startTime":"0","endTime":"0","summary":"阿斯利康(AZN)今日盘中大涨5.02%，表现强势。消息面上，公司最新发布的2025年业绩表现亮眼，全年总营收达587.39亿美元，同比增长8%，其中中国区营收66.54亿美元创历史新高。同时，公司宣布了未来几年在中国的巨额投资计划，彰显了对该市场长期增长的信心。此外，公司在热门减肥药领域的管线取得关键进展，其口服GLP-1受体激动剂elecoglipron在2b期临床试验中达到主要终点，即将进入三期临床开发阶段，这为公司在竞争激烈的减肥药市场增添了重要筹码。公司对2026年业绩给出了中高个位数增长的乐观预期，多重利好共同推动了股价的上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AZN"],"gpt_icon":0},{"id":"2610677847","title":"1至8批国家集采药品接续采购开标；阿斯利康去年全球总营收达587.39亿美元丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2610677847","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610677847?lang=zh_cn&edition=full","pubTime":"2026-02-11 07:08","pubTimestamp":1770764904,"startTime":"0","endTime":"0","summary":"丨2026年2月11日星期三丨NO.11至8批国家集采药品接续采购开标据央视新闻2月10日报道，记者从国家医保局获悉，1至8批国家集采药品新一轮接续采购开标产生拟中选结果，涉及316种常用药品，1020家企业的4163个产品获得拟中选资格。本次接续采购的药品覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系统、消化系统等26个治疗领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602113647093451.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113647093451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AZN","09939","159938"],"gpt_icon":0},{"id":"2610296606","title":"阿斯利康(AZN.US)拟走“低价高量”路线 进军全球减肥药市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2610296606","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610296606?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:22","pubTimestamp":1770733350,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英国制药巨头阿斯利康正计划以“改良现有药物＋更具竞争力的定价＋新兴市场经验”为核心策略，切入竞争激烈且持续升温的全球减肥药市场。Soriot曾将阿斯利康打造为肿瘤药物领域的重要玩家，如今正推动多款新一代减肥药加速上市。Soriot在公司公布第四季度财报后表示，现有减肥药效果显著，但仍有改进空间，包括提升患者依从性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康(AZN.US)拟走“低价高量”路线 进军全球减肥药市场","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","LU0320765992.SGD","LU1829250122.USD","LU2462157665.USD","LU2236285917.USD","LU2417539215.USD","BK4568","LU2456880835.USD","AZN","LU0889565916.HKD","BK4007","BK4585","BK4588"],"gpt_icon":0},{"id":"2610647820","title":"美股前瞻 | 三大股指期货齐涨 零售销售数据公布前美债抢跑“降息行情”","url":"https://stock-news.laohu8.com/highlight/detail?id=2610647820","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610647820?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:15","pubTimestamp":1770725744,"startTime":"0","endTime":"0","summary":"盘前市场动向1. 2月10日(周二)美股盘前，美股三大股指期货齐涨。市场消息市场抢跑“降息行情”：零售销售数据公布前，美债收益率持续走低。不过知情人士强调，这项大规模关税豁免计划目前仍在调整中，尚未得到特朗普签字批准。四季度癌症药物销售额增长 20%，达到 70.3 亿美元，但心血管药物收入下降 6%，至 30.5 亿美元，部分原因","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4535","BK4581","GOOGL","SRTY","KO","BK4588","IWN","HMC","GOVT","PHG","UWM","BP","RWM","TZA","AZN","IWO","BK4550","SHY","BK4585","TNA","MNQmain","IEF","IEI","TSM","BK4534","TWM","ON"],"gpt_icon":0},{"id":"2610431616","title":"阿斯利康(AZN.US)CFO：美国定价影响已纳入2026年业绩指引，该影响在一定程度上存在。","url":"https://stock-news.laohu8.com/highlight/detail?id=2610431616","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610431616?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:51","pubTimestamp":1770717069,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2417539215.USD","AZN","BK4007","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","LU1829250122.USD","BK4568","LU2236285917.USD","BK4588","BK4585","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2610061245","title":"阿斯利康2025年营收587.39亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610061245","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610061245?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:27","pubTimestamp":1770712065,"startTime":"0","endTime":"0","summary":"南方财经2月10日电，阿斯利康发布2025全年财报，全球总营收达587.39亿美元，同比增长8%，阿斯利康中国2025年总营收达66.54亿美元，同比增长4%，生物制药、肿瘤、罕见病三大业务领域均实现增长。今年1月29日，阿斯利康宣布到2030年将在中国投资逾1000亿元人民币（150亿美元），以扩大在药品生产与研发领域的布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646692714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AZN"],"gpt_icon":0},{"id":"1147357626","title":"阿斯利康2025年产品销售额同比增长9%，核心每股收益同比增长11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147357626","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147357626?lang=zh_cn&edition=full","pubTime":"2026-02-10 15:43","pubTimestamp":1770709431,"startTime":"0","endTime":"0","summary":"在各个治疗领域都取得了强劲的商业表现。","market":"us","thumbnail":"https://static.tigerbbs.com/3f18b4ef115990dc34ed7f9d372cbf4d","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3f18b4ef115990dc34ed7f9d372cbf4d"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康2025年产品销售额同比增长9%，核心每股收益同比增长11%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","AZN.UK"],"gpt_icon":0},{"id":"2610636394","title":"康泰生物与阿斯利康4亿美元合作告吹，涉疫苗研发生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2610636394","media":"新京报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610636394?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:53","pubTimestamp":1770630780,"startTime":"0","endTime":"0","summary":"彼时，双方在协议中约定，公司和阿斯利康计划在经开区共同成立合资公司，开展全球创新疫苗在中国地区的开发注册、本地化生产和商业化。康泰生物2024年营利双降，营收为26.52亿元，同比下降23.75%；实现净利润2.02亿元，同比下滑76.59%。2025年康泰生物则增收不增利。康泰生物表示，因四联苗受百白破免疫程序调整、营业成本上升及研发投入增加等因素影响，致使2025年度净利润较上年同期下降。","market":"hk","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl882026291747522902791.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl882026291747522902791.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1770630815168378.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1770630815168378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["LU2236285917.USD","BK0046","LU1829250122.USD","LU0320765992.SGD","LU0889565916.HKD","BK4568","BK0239","LU2456880835.USD","LU2462157665.USD","159646","300601","BK0201","BK4585","BK4007","LU0109394709.USD","AZN","BK4588","LU2417539215.USD"],"gpt_icon":0},{"id":"2609270915","title":"28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2609270915","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609270915?lang=zh_cn&edition=full","pubTime":"2026-02-08 12:13","pubTimestamp":1770523980,"startTime":"0","endTime":"0","summary":"康泰生物称“市场环境剧烈变化”。 康泰生物与阿斯利康投资（中国）有限公司设立合资疫苗企业的计划最终还是告吹了。 近日，康泰生物发布公告称，经各方审慎评估与友好协商，决定终止《经济发展合作协议》《条款清单》及对外投资设立合资公司事项。合资公司也将成为阿斯利康在中国首个且唯一的疫苗生产基地。 截至目前，合资公司尚未成立，康泰生物也尚未实际出资。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-08/doc-inhmapyc9468285.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-08/doc-inhmapyc9468285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300601","LU2456880835.USD","LU2417539215.USD","LU0320765992.SGD","LU2236285917.USD","BK4588","LU2462157665.USD","BK0046","BK4568","LU0889565916.HKD","BK0239","BK4585","159646","LU0109394709.USD","BK4007","BK0201","LU1829250122.USD","AZN"],"gpt_icon":0},{"id":"2609552481","title":"阿斯利康(AZN.US)双抗1类新药在中国获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2609552481","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609552481?lang=zh_cn&edition=full","pubTime":"2026-02-06 14:51","pubTimestamp":1770360715,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，中国国家药监局药品审评中心官网公示显示，阿斯利康申报的1类新药注射用AZD1163获批临床，拟开发治疗类风湿关节炎。2025 ACR年会首次公布了AZD1163在健康志愿者中的安全性、耐受性、药代动力学特性及其对系统性PAD酶活性影响的药效学数据研究。研究表明，AZD1163的暴露量呈剂量比例性增加，皮下给药后最大浓度出现在第10天。本次该产品在中国获批临床，意味着其在中国的临床研究即将开展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康(AZN.US)双抗1类新药在中国获批临床","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4007","LU0109394709.USD","AZN","LU2462157665.USD","LU2236285917.USD","LU1829250122.USD","LU2456880835.USD","BK4568","LU0889565916.HKD","BK4585","BK4588","LU0320765992.SGD","LU2417539215.USD"],"gpt_icon":0},{"id":"2608824783","title":"Saphnelo皮下剂型申请遭FDA驳回，阿斯利康：承诺与FDA密切合作以尽快推进申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2608824783","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608824783?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:16","pubTimestamp":1770113773,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","LU0109394709.USD","AZN","LU2462157665.USD","LU2236285917.USD","LU1829250122.USD","LU2456880835.USD","BK4568","LU0889565916.HKD","BK4585","BK4588","LU0320765992.SGD","LU2417539215.USD"],"gpt_icon":0},{"id":"2608234829","title":"阿斯利康狼疮药自行注射剂型申请遭FDA驳回","url":"https://stock-news.laohu8.com/highlight/detail?id=2608234829","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608234829?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:25","pubTimestamp":1770110748,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2456880835.USD","LU0889565916.HKD","BK4007","LU1829250122.USD","BK4585","BK4568","AZN","LU0109394709.USD","LU2236285917.USD","LU2417539215.USD","LU0320765992.SGD","LU2462157665.USD","BK4588"],"gpt_icon":0},{"id":"2608294608","title":"股价一度跌近2%！阿斯利康(AZN.US)狼疮药自行注射剂型申请遭FDA驳回","url":"https://stock-news.laohu8.com/highlight/detail?id=2608294608","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608294608?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:16","pubTimestamp":1770110175,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国食品药品监督管理局近日驳回了阿斯利康狼疮治疗药物的自行注射剂型上市申请，不过这家英国制药企业表示，目前仍在与监管机构沟通，推进该申请的审批进程。此次阿斯利康提交的为皮下注射剂型申请，若获批，患者可实现每周自行注射给药。阿斯利康方面披露，全球范围内受该疾病困扰的患者超340万人。据悉，FDA预计将在今年上半年对阿斯利康提交的补充申请作出审批决定，在此期间，该药物的静脉注射剂型仍正常供应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU0320765992.SGD","LU0109394709.USD","LU2456880835.USD","LU2462157665.USD","LU1829250122.USD","BK4588","BK4585","LU2417539215.USD","LU0889565916.HKD","AZN","BK4568","LU2236285917.USD"],"gpt_icon":0},{"id":"1136517370","title":"财报前瞻｜阿斯利康本季度营收预计增8.99%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1136517370","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136517370?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:00","pubTimestamp":1770084035,"startTime":"0","endTime":"0","summary":"阿斯利康将在2026年02月10日发布最新季度财报，市场关注肿瘤与罕见病业务的延续增长与盈利质量的变化。市场一致预期本季度总收入为155.11亿美元，同比增加8.99%；EBIT为47.13亿美元，同比增加12.06%；调整后每股收益为1.03美元，同比下降1.91%。围绕利润率指标，当前一致预期未提供毛利率与净利率的本季度具体预测；公司上季度财报未给出本季度毛利率或净利率的明确预估。根据近期机构观点的汇总，市场对阿斯利康的立场偏向看多。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜阿斯利康本季度营收预计增8.99%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"gpt_icon":0},{"id":"2608852370","title":"加码美国市场：阿斯利康登陆纽交所，伦敦地位或被削弱","url":"https://stock-news.laohu8.com/highlight/detail?id=2608852370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608852370?lang=zh_cn&edition=full","pubTime":"2026-02-02 19:59","pubTimestamp":1770033595,"startTime":"0","endTime":"0","summary":"公司表示，此举将使其在英国、瑞典和美国的上市地位具有同等分量。此后，美国投资者将更容易购买阿斯利康的完整股票，这增加了该公司在伦敦上市地位相关性可能下降的可能性。在美国总统特朗普关税计划带来的压力下，阿斯利康承诺到2030年在美国投资500亿美元。阿斯利康的 ADR 交易量在截至2024年的五年间增长了34%，而同期伦敦股市的成交量增长不足8%。","market":"us","thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400590.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"加码美国市场：阿斯利康登陆纽交所，伦敦地位或被削弱","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0889565916.HKD","LU2236285917.USD","LU2417539215.USD","LU2456880835.USD","LU2462157665.USD","BK4588","BK4585","LU1829250122.USD","AZN","BK4568"],"gpt_icon":1},{"id":"2608833532","title":"中金：石药集团(01093)与阿斯利康达成重磅合作 维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2608833532","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608833532?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:37","pubTimestamp":1769996220,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持石药集团“跑赢行业”评级，考虑对外授权持续兑现上调目标价9.1%到12港元。石药集团公告与阿斯利康签订研发合作与授权协议。中金主要观点如下：中国创新药授权出海再获里程碑式突破根据公告，石药集团及附属公司授权阿斯利康在全球范围内独家开发、生产和商业化8个创新长效多肽药物项目，阿斯利康将支付合计12亿美元预付款以及后续累计最高35亿/138亿美元的开发/销售里程碑款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZN","01093"],"gpt_icon":0},{"id":"2607604639","title":"阿斯利康全球CEO：中国在全球医药创新生态中不可或缺","url":"https://stock-news.laohu8.com/highlight/detail?id=2607604639","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607604639?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:16","pubTimestamp":1769779009,"startTime":"0","endTime":"0","summary":"中新社北京1月30日电(记者尹倩芸迟瀚宇)阿斯利康全球首席执行官苏博科(PascalSoriot)30日在北京接受中新社记者采访时表示，中国已成为全球医药创新生态中不可或缺的组成部分。阿斯利康近日宣布，计划于2030年前在中国投资逾1000亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303637319957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637319957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4568","LU1829250122.USD","BK1161","BK1574","159938","BK4007","LU2236285917.USD","BK1515","09939","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","BK4585","LU2417539215.USD","LU0109394709.USD","AZN","LU0889565916.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":0.0208},{"period":"1month","weight":0.1181},{"period":"3month","weight":0.1241},{"period":"6month","weight":0.3044},{"period":"1year","weight":0.3777},{"period":"ytd","weight":0.1337}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018334},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}